1133 related articles for article (PubMed ID: 10597778)
41. Virological and immunological outcomes in HIV-1-infected Chinese patients treated with a combination of Efavirenz and Indinavir for 48 weeks.
Li L; Wei FL; Mei S; Feng X; Yao J; Jin X; Cao YZ
Chin Med J (Engl); 2004 Mar; 117(3):347-52. PubMed ID: 15043771
[TBL] [Abstract][Full Text] [Related]
42. Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection.
Kaufmann GR; Zaunders JJ; Cunningham P; Kelleher AD; Grey P; Smith D; Carr A; Cooper DA
AIDS; 2000 Dec; 14(17):2643-51. PubMed ID: 11125882
[TBL] [Abstract][Full Text] [Related]
43. Comparison of CD8(+) T-cell subsets in HIV-infected rapid progressor children versus non--rapid progressor children.
Paul ME; Shearer WT; Kozinetz CA; Lewis DE
J Allergy Clin Immunol; 2001 Aug; 108(2):258-64. PubMed ID: 11496243
[TBL] [Abstract][Full Text] [Related]
44. CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency.
Liu Z; Cumberland WG; Hultin LE; Kaplan AH; Detels R; Giorgi JV
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Aug; 18(4):332-40. PubMed ID: 9704938
[TBL] [Abstract][Full Text] [Related]
45. Cd38 expression on Cd8+ T cells in Human immunodeficiency virus 1-positive adults treated with HAART.
Beran O; Holub M; Spála J; Kalanin J; Stanková M
Acta Virol; 2003; 47(2):121-4. PubMed ID: 14524479
[TBL] [Abstract][Full Text] [Related]
46. Changes in levels of immune activation and reconstitution markers among HIV-1-infected Africans receiving antiretroviral therapy.
Koblavi-Dème S; Maran M; Kabran N; Borget MY; Kalou M; Kestens L; Maurice C; Sassan-Morokro M; Ekpini ER; Roels TH; Chorba T; Nkengasong JN
AIDS; 2003 Jul; 17 Suppl 3():S17-22. PubMed ID: 14565605
[TBL] [Abstract][Full Text] [Related]
47. CD8+ lymphocyte activation at human immunodeficiency virus type 1 seroconversion: development of HLA-DR+ CD38- CD8+ cells is associated with subsequent stable CD4+ cell levels. The Multicenter AIDS Cohort Study Group.
Giorgi JV; Ho HN; Hirji K; Chou CC; Hultin LE; O'Rourke S; Park L; Margolick JB; Ferbas J; Phair JP
J Infect Dis; 1994 Oct; 170(4):775-81. PubMed ID: 7930717
[TBL] [Abstract][Full Text] [Related]
48. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response.
Hatano H; Hayes TL; Dahl V; Sinclair E; Lee TH; Hoh R; Lampiris H; Hunt PW; Palmer S; McCune JM; Martin JN; Busch MP; Shacklett BL; Deeks SG
J Infect Dis; 2011 Apr; 203(7):960-8. PubMed ID: 21402547
[TBL] [Abstract][Full Text] [Related]
49. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression.
Liu Z; Cumberland WG; Hultin LE; Prince HE; Detels R; Giorgi JV
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Oct; 16(2):83-92. PubMed ID: 9358102
[TBL] [Abstract][Full Text] [Related]
50. Quantitative alterations of the functionally distinct subsets of CD4 and CD8 T lymphocytes in asymptomatic HIV infection: changes in the expression of CD45RO, CD45RA, CD11b, CD38, HLA-DR, and CD25 antigens.
Benito JM; Zabay JM; Gil J; Bermejo M; Escudero A; Sánchez E; Fernández-Cruz E
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Feb; 14(2):128-35. PubMed ID: 9052721
[TBL] [Abstract][Full Text] [Related]
51. Virus burden in long-term survivors of human immunodeficiency virus (HIV) infection is a determinant of anti-HIV CD8+ lymphocyte activity.
Ferbas J; Kaplan AH; Hausner MA; Hultin LE; Matud JL; Liu Z; Panicali DL; Nerng-Ho H; Detels R; Giorgi JV
J Infect Dis; 1995 Aug; 172(2):329-39. PubMed ID: 7622874
[TBL] [Abstract][Full Text] [Related]
52. Adrenaline-induced mobilization of T cells in HIV-infected patients.
Søndergaard SR; Cozzi Lepri A; Ullum H; Wiis J; Hermann CK; Laursen SB; Qvist J; Gerstoft J; Skinhøj P; Pedersen BK
Clin Exp Immunol; 2000 Jan; 119(1):115-22. PubMed ID: 10606972
[TBL] [Abstract][Full Text] [Related]
53. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia.
Karlsson AC; Younger SR; Martin JN; Grossman Z; Sinclair E; Hunt PW; Hagos E; Nixon DF; Deeks SG
AIDS; 2004 Apr; 18(7):981-9. PubMed ID: 15096800
[TBL] [Abstract][Full Text] [Related]
54. CD8+CD38+ and CD8+DR+ peripheral blood lymphoid subsets of HIV-infected intravenous drug abusers correlate with CD4+ cell counts and proliferation to mitogens.
Echaniz P; Arrizabalaga J; Iribarren JA; Cuadrado E
Cell Immunol; 1993 Aug; 150(1):72-80. PubMed ID: 7688270
[TBL] [Abstract][Full Text] [Related]
55. HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation.
Steel A; Cox AE; Shamji MH; John L; Nelson M; Henderson DC; Gotch FM; Gazzard BG; Kelleher P
Antivir Ther; 2007; 12(6):971-5. PubMed ID: 17926652
[TBL] [Abstract][Full Text] [Related]
56. CD4+ T cell recovery beyond the first year of complete suppression of viral replication during highly active antiretroviral therapy is not influenced by CD8+ T cell activation.
Benito JM; Lopez M; Lozano S; Ballesteros C; Capa L; Martinez P; Gonzalez-Lahoz J; Soriano V
J Infect Dis; 2005 Dec; 192(12):2142-6. PubMed ID: 16288380
[TBL] [Abstract][Full Text] [Related]
57. CD4 T cell recovery is slower in patients experiencing viral load rebounds during HAART.
Scott-Algara D; Aboulker JP; Durier C; Badell E; Marcellin F; Prud'homme M; Jouanne C; Meiffredy V; Brun-Vezinet F; Pialoux G; Raffi F;
Clin Exp Immunol; 2001 Nov; 126(2):295-303. PubMed ID: 11703374
[TBL] [Abstract][Full Text] [Related]
58. Characterizing the immune system after long-term undetectable viral load in HIV-1-infected children.
Resino S; Galán I; Bellón JM; Navarro ML; León JA; Muñoz-Fernandez MA
J Clin Immunol; 2003 Jul; 23(4):279-89. PubMed ID: 12959220
[TBL] [Abstract][Full Text] [Related]
59. Low-level viremia and proviral DNA impede immune reconstitution in HIV-1-infected patients receiving highly active antiretroviral therapy.
Ostrowski SR; Katzenstein TL; Thim PT; Pedersen BK; Gerstoft J; Ullum H
J Infect Dis; 2005 Feb; 191(3):348-57. PubMed ID: 15633093
[TBL] [Abstract][Full Text] [Related]
60. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART).
Hazenberg MD; Stuart JW; Otto SA; Borleffs JC; Boucher CA; de Boer RJ; Miedema F; Hamann D
Blood; 2000 Jan; 95(1):249-55. PubMed ID: 10607709
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
